Retrospective Comparative Analysis of Opioid Use and Intra-Articular Corticosteroid Injections Before and After Initial Treatment of Knee Osteoarthritis with Hylan G-F 20
Victor Khangulov,1 Xuan Zhang,1 Sibyl H Munson,1 Fred Peyerl,1 Francoise Rey2 1Department of Health Economics and Outcomes Research, Boston Strategic Partners, Inc., Boston, MA, USA; 2Sanofi, Paris, FranceCorrespondence: Victor Khangulov 15 Graham Street #2, Jersey City, NJ 07307, USATel +1-646-397-...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dea8110791654670b5c2e6be8e0a8413 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Victor Khangulov,1 Xuan Zhang,1 Sibyl H Munson,1 Fred Peyerl,1 Francoise Rey2 1Department of Health Economics and Outcomes Research, Boston Strategic Partners, Inc., Boston, MA, USA; 2Sanofi, Paris, FranceCorrespondence: Victor Khangulov 15 Graham Street #2, Jersey City, NJ 07307, USATel +1-646-397-9420Email vkhangulov@gmail.comBackground: Knee osteoarthritis (OA) is a painful condition affecting > 250 million people worldwide and is a leading cause of disability. Intra-articular (IA) corticosteroids and/or oral opioids are often recommended for the management of knee OA pain. There are, however, concerns regarding their safety and tolerability.Study Question: Do patients diagnosed with knee OA show a decrease in opioids or IA corticosteroid injections prescribed/administered in hospitals following hylan G-F 20 treatment?Study Design: This case-crossover, retrospective study using Health Facts®, a de-identified electronic health records database, enrolled patients ≥ 18 years with knee OA treated with hylan G-F 20 between January 1, 2000 and March 31, 2016, with data within 6 months before/after treatment.Measures and Outcomes: Primary endpoints compared days on opioids, amounts of opioids, and number of IA corticosteroid injections before/after hylan G-F 20 treatment via paired t-tests.Results: A total of 513 patients were qualified for analysis. In the opioid cohort, the average total number of days on opioids (N = 50; 5.0 vs 13.5 days; P = 0.007) and average total amount of opioids (N = 44; 165.4 morphine mg equivalents [MME] vs 493.7 MME; P = 0.013) were lower 6 months after hylan G-F 20 treatment than 6 months before treatment. In the IA corticosteroid cohort, the average number of IA corticosteroid injections decreased after hylan G-F 20 treatment (N = 36; 0.56 in the 6-month follow-up vs 1.39 before treatment; P < 0.0001). Additional time frames of 1– 5 months before and after treatment were examined; similar conclusions were drawn for patients with > 2 months of data.Conclusion: Patients with knee OA previously treated with opioids or IA corticosteroid injections who received hylan G-F 20 demonstrated statistically significant decreases in these medications > 2 months following hylan G-F 20 treatment versus > 2 months before treatment.Keywords: corticosteroids, opioids, osteoarthritis, viscosupplementation, hyaluronic acid, hylan G-F 20 |
|---|